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We showed that nitric oxide (NO) signaling is decreased in the
pulmonary vasculature before the development of endothelial
dysfunction in a lamb model of congenital heart disease and in-
creased pulmonary blood flow (Shunt). The elucidation of the
molecular mechanism by which this occurs was the purpose of
this study. Here, we demonstrate that concentrations of the endog-
enous NO synthase (NOS) inhibitor, asymmetric dimethylarginine
(ADMA), are elevated, whereas the NOS cofactor tetrahydrobiop-
terin (BH4) is decreased in Shunt lambs. Our previous studies dem-
onstrated that ADMA decreases heat shock protein–90 (Hsp90)
chaperone activity, whereas other studies suggest that guanosine-
59-triphosphate cyclohydrolase 1 (GCH1), the rate-limiting enzyme in
the generation of BH4, may be a client protein for Hsp90. Thus, we
determined whether increases in ADMA could alter GCH1 protein
and activity. Our data demonstrate that ADMA decreased GCH1
protein, but not mRNA concentrations, in pulmonary arterial endo-
thelial cells (PAECs) because of the ubiquitination and proteasome-
dependent degradation of GCH1. We also found that Hsp90–GCH1
interactions were reduced, whereas the association of GCH1 with
Hsp70 and the C-terminus of Hsp70-interacting protein (CHIP)
increased in ADMA-exposed PAECs. The overexpression of CHIP
potentiated, whereas a CHIP U-box domain mutant attenuated,
ADMA-induced GCH1 degradation and reductions in cellular BH4
concentrations. We also found in vivo that Hsp90/GCH1 interactions
are decreased, whereas GCH1–Hsp70 and GCH1–CHIP interactions
and GCH1 ubiquitination are increased. Finally, we found that
supplementation with L-arginine restored Hsp90–GCH1 interactions
and increased both BH4 and NOx concentrations in Shunt lambs. In
conclusion, increased concentrations of ADMA can indirectly alter
NO signaling through decreased cellular BH4 concentrations, sec-
ondary to the disruption of Hsp90–GCH1 interactions and the CHIP-
dependent proteasomal degradation of GCH1.
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Nitric oxide (NO), produced by endothelial NO synthase
(eNOS), plays a role in controlling vascular tone. Accumulating
evidence suggests that a decrease in NO signaling causes en-
dothelial dysfunction in a number of cardiovascular diseases. We
recently found, using a lamb model of congenital heart disease
(CHD) with increased pulmonary blood flow (Shunt), that NO
signaling is compromised before the development of endothelial
dysfunction, and this correlates with an increase in eNOS
uncoupling. NOS uncoupling is a complex process that can be
induced by decreases in the availability of the substrate L-arginine
or the cofactor tetrahydrobiopterin (BH4), or as we recently
showed, by increases in the cellular concentrations of asymmetric
dimethyarginine (ADMA) (1). A large body of evidence supports
the conclusion that increased concentrations of ADMA contrib-
ute to the development of endothelial dysfunction (2). ADMA is
constantly formed during physiologic protein turnover, and it is
released from the hydrolysis of methylated proteins (3, 4).
Increased ADMA concentrations were reported in a variety of
pathologic conditions affecting the cardiovascular system (3, 4),
including pulmonary hypertension (5). However, the mechanisms
by which ADMA exerts its effects on endothelial function have
not been adequately elucidated.
A large number of studies showed that suboptimal concen-
trations of BH4 induce endothelial dysfunction through eNOS
uncoupling (6). In cells, BH4 can be produced by two different
metabolic pathways: the de novo and the salvage pathways.
GTP cyclohydrolase I (GCH1) is the first, rate-limiting enzyme
in the de novo pathway of BH4 biosynthesis (7). Recent studies
suggested that GCH1 may be a client protein for Hsp90 (8),
and the conditions that reduce concentrations of BH4 are also
the conditions that reduce Hsp90 chaperone activity (1, 9),
suggesting that the activity of GCH1 may be influenced by its
interactions with Hsp90. We previously showed that increasing
the cellular concentrations of ADMA l decreases Hsp90
chaperone activity in pulmonary arterial endothelial cells
(PAECs) (1). Thus, the purpose of this study was to begin
elucidating the molecular mechanisms that underlie the in-
crease in eNOS uncoupling that we previously showed in our
Shunt model, and to determine if a link existed between
increases in ADMA concentrations and alterations in BH4
biosynthesis.
Here we report, both in vitro and in vivo, that increased
concentrations of ADMA result in decreased BH4 concentrations
through the disruption of the Hsp90–GCH1 complex, leading to
the C-terminus of Hsp70-interacting protein (CHIP)–dependent
ubiquitin-mediated proteasomal degradation of GCH1. Together,
our data indicate that ADMA can both directly, through
competition with L-arginine for the active site of eNOS, and
indirectly, through its modulation of Hsp90 chaperone activity
and decreased BH4, produce eNOS uncoupling.
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MATERIALS AND METHODS
Surgical Preparation and Care
Eighteen mixed-breed Western pregnant ewes (at 137–141 days of
gestation; term, 145 days) were operated upon, as previously described
(10) (see also the online supplement). All protocols and procedures
were approved by the Committees on Animal Research at the
University of California at San Francisco, the Medical College of
Georgia, and the German Heart Center.
Hemodynamic Measurements
Pulmonary arterial and right and left atrial pressures were measured as
described in the online supplement.
Measurement of ADMA Concentrations
Concentrations of ADMA were analyzed using high-performance
liquid chromatography (HPLC), as we described elsewhere (1).
Measurement of Dimethylarginine
Dimethylaminohydrolase Activity
The activity of dimethylarginine dimethylaminohydrolase (DDAH) in
tissues was assessed directly by measuring the amount of ADMA
metabolized by this enzyme, as previously described (11).
Cell Culture and Treatment
Primary cultures of ovine PAECs were isolated, as described pre-
viously (12), and were treated as described in the online supplement.
Quantification of Biopterin Concentrations According
to HPLC
Concentrations of BH4 were determined using the differential iodine
oxidation method, as we previously described (13, 14). Levels were
normalized for protein concentration, using the Bradford assay.
Purification of Recombinant Human eNOS
Recombinant human eNOS was purified from Escherichia coli strain
BL21 (DE3) pLysS (EMD4Biosciences, San Diego, CA) containing
the poly-His-pCWeNOS vector, as previously described (15).
Plasmids and Transient Transfection of PAECs
The pcDNA3 expression constructs encoding the Myc epitope-tagged
human wild-type and point mutant (K260Q) CHIP were described
previously (16, 17). PAECs were seeded onto 6-well plates at a density
of approximately 16,000 cells/cm2. Cells were transiently transfected
with wild-type CHIP, a U-box domain mutant CHP, or the parental
vector (pcDNA3), using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions.
Immunoprecipitation and Western Blot Analysis
Immunoprecipitation and Western blot analysis were performed as
described in the online supplement.
Determination of mRNA Concentrations
For cell-culture studies to determine concentrations of GCH1 mRNA,
semiquantitative RT-PCR was used as described in the online supplement.
For in vivo studies using peripheral lung tissue, quantitative RT-PCR,
involving SYBR green I dye for the specific detection of double-stranded
DNA, was used as described in the online supplement.
Shear Stress
Laminar shear stress (20 dyn/cm2) was applied using a cone-plate
viscometer, as described previously (18, 19).
Determination of NOx Concentrations
A chemiluminescence method was used, as described in the online
supplement.
Detection of Ubiquitinated GCH1
Ubiquitinated GCH1 was enriched using a ubiquitinated protein
enrichment kit (Calbiochem, Gibbstown, NJ), according to the man-
ufacturer’s guidelines. Samples were separated by SDS-PAGE and
analyzed by Western blotting, using a specific antiserum raised against
GCH1 (13).
Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 4.01
for Windows (GraphPad Software, La Jolla, CA). Means 6 SEMs were
calculated for all samples, and significance was determined either by
unpaired t test (for two groups) or by ANOVA (for > 3 groups), with
Newman-Keuls post hoc testing. When data were non-normally
distributed, nonparametric testing was used (with the Wilcoxon
signed-rank test for two groups, and the Kruskal-Wallis test for > 3
groups). P , 0.05 was considered significant.
RESULTS
Hemodynamics
The hemodynamic data for the 2-week-old control and Shunt
lambs are shown in Table 1. Pulmonary arterial pressure, left
atrial pressure, and left pulmonary blood flow were significantly
greater in Shunt lambs than in age-matched control lambs
(Table 1). In addition, a significant difference in pulmonary-
to-systemic blood flow ratio occurred in Shunt lambs (Table 1).
No significant differences were evident in mean blood pressure,
heart rate, and right atrial pressure (Table 1).
Peripheral Lung Concentrations of ADMA
and Tetrahydrobiopterin
Our previous studies showed an early increase in eNOS uncou-
pling in Shunt lambs, although the mechanisms remain unclear (1,
20). To begin elucidating the mechanism underlying this uncou-
pling process, we initially determined whether alterations oc-
curred in either ADMA or BH4 in the Shunt lambs. Our data
indicate that Shunt lambs have significantly higher concentra-
tions of peripheral lung-tissue ADMA (Figure 1A), resulting in
a significant decrease in the peripheral lung L-arginine/ADMA
ratio (Figure 1B). This increase in ADMA concentrations
correlates with a decrease in DDAH activity (Figure 1C). In
addition, Shunt lambs exhibit a significant decrease in BH4
concentrations (Figure 1D), correlating with a significant de-
crease in GCH1 protein concentrations (Figure 1E) but not
GCH1 mRNA (Figure 1F). Together, these changes significantly
decrease tissue NOx concentrations in Shunt lambs (Figure 1G).
To begin determining the relative effects of these changes in
ADMA and BH4 on NO signaling, we used human recombinant
protein and matched the ADMA/L-arginine ratio and BH4
concentrations in control and Shunt lambs, both individually





PAP (mean, mm Hg) 21.6 6 4.3* 15.4 6 3.2
LAP (mean, mm Hg) 6.5 6 4.1* 3.1 6 1.9
RAP (mean, mm Hg) 4.9 6 3.2 2.5 6 1.4
Mean BP (mm Hg) 75.8 6 31.5 65.0 6 7.2
Left pulmonary flow (ml per minute/kg) 166.0 6 15.7* 55.5 6 15.9
Heart rate (beats/minute) 162.7 6 30.4 177.4 6 26.7
Qp/Qs 3.4 6 1.2* 1.1 6 0.1
Definition of abbreviations: PAP, pulmonary arterial pressure; LAP, left atrial
pressure; RAP, right atrial pressure; BP, systemic blood pressure; Qp/Qs,
pulmonary-to-systemic blood flow ratio (n 5 6 for each group). Data are
mean 6 SD
* Indicates P < 0.05 vs. 2-week control lambs.
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and in tandem. Our data demonstrate that increasing the ratio of
ADMA to L-arginine to match that of Shunt lambs significantly
decreased the generation of NO to a similar extent as when
matching the decrease in BH4 concentrations (Figure 1H). When
we matched the increase in ADMA and the decrease in BH4
observed in Shunt lambs, a synergistic decrease in the generation
of NO was evident (Figure 1H).
Effect of ADMA on BH4 and GCH1 Concentrations in PAECs
Recent studies suggested that GCH1 may be a client protein for
Hsp90 (8), and we previously showed that increasing the
cellular concentrations of ADMA decreased Hsp90 chaperone
activity in PAECs (1). Thus, we initiated a series of cell-culture
studies to determine if increased concentrations of ADMA
were modulating BH4 concentrations through alterations in
Hsp90 chaperone activity. A time-course analysis of PAECs
exposed to increased concentrations of ADMA demonstrated
that BH4 concentrations were significantly decreased after
4 hours of exposure, and this decrease was sustained through
24 hours (Figure 2A). We also analyzed the effects of ADMA
on both GCH1 mRNA and protein concentrations, to deter-
mine if any changes were detectable before the decrease in BH4
concentrations. Our data indicate that exposure of PAECs to
ADMA for 2 hours significantly lowered the protein concen-
trations of GCH1 (Figure 2B), but as in the Shunt lambs, GCH1
mRNA concentrations were unchanged (Figure 2C). These
changes resulted in a decrease in the generation of NO in
response to shear stress that could be reversed by the addition
of the BH4 precursor, sepiapterin (Figure 2D).
ADMA Disrupts the Hsp90–GCH1 Complex and Increases
Hsp70–GCH1 Interactions in PAECs
Using an immunoprecipitation–Western blot technique, we
revealed that GCH1 forms a complex with Hsp90 in PAECs
(Figure 3A), whereas the exposure of cells to ADMA led to
a significant decrease in this association (Figure 3A). Hsp90
client proteins are usually brought into the complex with Hsp90
through multiprotein Hsp90/Hsp70–based chaperone machin-
ery (21). Further, Hsp70 appears to be involved in both the
folding and degradation of Hsp90-client proteins (22). Again,
using an immunoprecipitation–Western blot technique, we
found that exposure to ADMA significantly increased the
interaction of GCH1 with Hsp70 (Figure 3B).
ADMA Mediates GCH1 Degradation via
a Ubiquitination–Proteasome Pathway in PAECs
Increasing evidence suggests that the selective degradation of
many proteins in eukaryotic cells is mediated by protein ubiq-
uitination (23). To investigate the role of ubiquitination in the
Figure 1. Concentrations of asymmetric dimethyarginine
(ADMA) and tetrahydrobiopterin (BH4) are altered in lambs
with increased pulmonary blood flow. ADMA (A), the L-arginine/
ADMA ratio (B), and dimethylarginine dimethylaminohydrolase
(DDAH) activity (C) were determined in peripheral lungs of
Shunt and control lambs. Concentrations of ADMA are signif-
icantly increased in Shunt lambs, whereas the L-arginine/ADMA
ratio and DDAH activity are significantly decreased. In addition,
concentrations of BH4 were also significantly decreased in
Shunt lambs, whereas concentrations of BH4 were restored by
supplementation with L-arginine (D). Protein extracts or total
RNA were also prepared from the peripheral lungs of Shunt and
control lambs. GTP cyclohydrolase I (GCH1) protein (E) and
mRNA (F) were then determined by Western blot analysis or
quantitative RT-PCR, respectively. The Western blot analysis
was performed using an antibody raised against GCH1. A
representative image is shown. Loading was normalized by
reprobing the membranes with an antibody specific to b-actin.
GCH1 protein concentrations were significantly decreased in
2-week-old Shunt lambs (E ). However, concentrations of GCH1
mRNA were unchanged (F ). These changes correlated with
a decrease in tissue NOx concentrations in Shunt lambs. NOx
concentrations were restored to control levels by supplemen-
tation with L-arginine (G). Values represent mean 6 SEM (n 5 6).
*P , 0.05 versus control lambs. To define the relative roles
of increased ADMA and decreased BH4 in the inhibition of
NO synthesis, purified human endothelial NO synthase (eNOS)
(80 ng) was incubated with 4 mM (control concentrations) or
1.6 mM (Shunt concentrations) of BH4 and 0.1 mM L-arginine
in the presence of ADMA levels that matched the L-arginine/
ADMA ratios we observed in either control or Shunt lambs. The
generation of NOx was then determined. Shunt concentrations
of ADMA or BH4 alone significantly decreased the generation
of NOx (H), whereas a synergistic decrease occurred in NOx
concentrations when Shunt concentrations of BH4 and ADMA
were added in combination (H). Values represent means 6 SEM
(n 5 6). *P , 0.05 versus control concentrations of BH4 and
ADMA. †P , 0.05 versus Shunt concentrations of ADMA or BH4
alone.
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decrease in GCH1 protein concentrations associated with in-
creased concentrations of ADMA, PAECs were pretreated with
the proteasome inhibitor MG132 in the presence or absence of
increased concentrations of ADMA. Exposure of PAECs to
ADMA, or MG132 alone, significantly increased the ubiquitina-
tion of GCH1 (Figure 4A), suggesting that the ADMA-mediated
degradation of GCH1 occurs via a ubiquitin-dependent mecha-
nism. To confirm this, we measured the effects of proteasome
inhibition on the ADMA-induced degradation of GCH1 and on
cellular BH4 concentrations. Our data indicate that the in-
hibition of proteasome attenuates the ADMA-induced decrease
in GCH1 protein concentrations (Figure 4B), and attenuates the
reduction in BH4 concentrations (Figure 4C). Similarly, the
decrease in NO generation in response to ADMA was reversed
in the presence of MG132 (Figure 4D).
CHIP Facilitates Both Basal and ADMA-Mediated GCH1
Degradation in PAECs
Previous studies identified CHIP as a ubiquitin ligase that
directs client protein degradation via the ubiquitin–proteasome
pathway (17). To assess whether CHIP is involved in the
ADMA-induced degradation of GCH1, we determined whether
GCH1 interacts with CHIP and the effects of ADMA on this
interaction. Our data indicate that ADMA increased the in-
teraction of GCH1 with CHIP in PAECs (Figure 5A). Next, we
examined the effects of CHIP overexpression on GCH1 protein
concentrations in PAECs. Cells were transiently transfected
with an expression construct for wild-type CHIP (pcDNA-myc-
CHIP) or the parental vector (pCDNA3), and the effects on
GCH1 protein concentrations were determined by Western blot
analysis. The overexpression of CHIP decreased GCH1 protein
concentrations in a dose-dependent manner (Figure 5B). Fur-
ther, we determined possible synergistic effects between CHIP
and ADMA on the interactions of GCH1 with Hsp90 and
Hsp70 in PAECs. Again, cells were transiently transfected with
wild-type CHIP and exposed to ADMA. We found that the
overexpression of CHIP in combination with the addition of
ADMA further reduced the Hsp90–GCH1 interaction, com-
pared with the overexpression of CHIP or ADMA treatment
alone (Figure 5C). The overexpression of CHIP, in combination
with the addition of ADMA, also significantly increased the
Hsp70–GCH1 interaction, compared with the overexpression of
CHIP or ADMA treatment alone (Figure 5D). Taken together,
our results suggest that CHIP or ADMA can individually
Figure 2. Effects of increased ADMA concentrations on
expression of GCH1 and BH4 concentrations in pulmonary
arterial endothelial cells (PAECs). PAECs were exposed
to an L-arginine/ADMA ratio of 5:1 to mimic the concen-
trations seen in Shunt lambs for up to 24 hours. Concen-
trations of BH4 in cell extracts were then measured by
high-performance liquid chromatography (HPLC) (A).
Concentrations of BH4 significantly decreased after
4 hours, and this decrease persisted through 24 hours of
exposure (A). In addition, protein extracts and total RNA
were prepared from cells exposed to ADMA for 2 hours
(a time that preceded the decrease in BH4 concentra-
tions). Western blot (B) and semiquantitative RT-PCR (C )
analyses were also performed. A representative image is
shown, along with a densitometric analysis indicating that
ADMA decreases GCH1 protein concentrations (B). Load-
ing was normalized by reprobing the membranes with an
antibody specific to b-actin. GCH1 mRNA concentrations
were unchanged (C ). Values represent mean 6 SEM (n 5
4). *P , 0.05 versus untreated cells. The decrease in
concentrations of BH4 induced by ADMA resulted in
a significant decrease in the generation of NO in response
to shear stress (15 minutes, 20 dyn/cm2), and this was
reversed by pretreatment with the BH4 precursor, sepiap-
terin (10 mM) (D). Values represent mean 6 SEM (n 5 6).
*P , 0.05 versus no shear. †P , 0.05 versus shear alone.
‡P , 0.05 versus shear 1 ADMA.
Figure 3. GCH1 is present in a complex with heat shock
protein–90 (Hsp90) in PAECs, and ADMA disrupts this
interaction. PAECs were exposed or not exposed to ADMA
for 2 hours, and then whole-cell lysates (1 mg) were
subjected to immunoprecipitation (IP), using an antibody
specific to Hsp90 (A) or Hsp70 (B) (2 mg), followed by
Western blot (IB) analysis using a specific antiserum raised
against GCH1. A representative image is shown for each
Western blot, including the control with IgG alone. Blots
were also stripped and reprobed for Hsp90 or Hsp70, to
normalize for the efficiency of immunoprecipitation. Den-
sitometric values were then obtained for each. GCH1 is
present in PAECs in a complex with both Hsp90 and
Hsp70, and ADMA reduces the interaction of GCH1 with
Hsp90 and enhances its interaction with Hsp70. Values
represent mean 6 SEM (n 5 4). *P , 0.05 versus control.
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modulate Hsp90–GCH1 and Hsp70–GCH1 interactions, and
that in combination, a synergistic effect on the interactions of
GCH1 with Hsp90 and Hsp70 occurs.
The U-Box Domain of CHIP Is Essential for ADMA-Mediated
GCH1 Degradation in PAECs
CHIP has a C-terminal U-box domain that is responsible for its
ubiquitin ligase activity (17). To test the effects of this domain on
the CHIP-facilitated, ADMA-mediated degradation of GCH1,
we used a U-box domain mutant CHIP (U-box-mCHIP) that
lacks the ability to ubiquitinate protein (17). PAECs were
trasnsiently transfected with wild-type CHIP, U-box-mCHIP,
or the parental vector (pCDNA3), and were then exposed or not
to ADMA. GCH1 protein concentrations and BH4/BH2 ratio
were subsequently determined by Western blot analysis or
HPLC. Western blot analysis demonstrated that U-box-mCHIP
exerted a dominant negative effect on the ADMA-mediated de-
crease in GCH1 protein concentrations (Figure 6A). Our results
also indicated that the overexpression of wild-type CHIP but not
U-box-mCHIP significantly lowered the BH4/BH2 ratio in
PAECs (Figure 6B). In the presence of ADMA, the BH4/BH2
ratio was further reduced in cells overexpressing wild-type CHIP
(Figure 6B). However, when cells were transfected with U-box-
mCHIP and exposed to ADMA, the BH4/BH2 ratio was not
altered (Figure 6B). We also found that the overexpression of
wild-type CHIP significantly decreased the shear-mediated
generation of NOx (Figure 6C). Further, the overexpression of
CHIP in combination with ADMA further reduced the pro-
duction of NOx, compared with the overexpression of CHIP or
ADMA treatment alone (Figure 6C). Conversely, the overexpres-
sion of the U-box-mCHIP significantly attenuated the ADMA-
mediated decrease in NOx generation (Figure 6C).
The CHIP–Ubiquitin Pathway Modifies GCH1 in a Lamb
Model of Pulmonary Hypertension Secondary to Increased
Pulmonary Blood Flow
Finally, we reexamined our lamb model to determine if the
changes in GCH1 protein concentrations (Figure 1) were
attributable to the same Hsp70–CHIP–ubiquitin pathway we
elucidated in culture. Our data indicate that the interaction of
GCH1 with Hsp90 is significantly decreased in the Shunt lamb
(Figures 7A and 7B), whereas Hsp70–GCH1 (Figure 7C) and
CHIP–GCH1 (Figure 7D) interactions are significantly in-
creased in Shunt lambs. Consistent with these findings, the
ubiquitination of GCH1 is significantly increased in Shunt lambs
(Figure 7E).
Supplementation with L-Arginine Preserves the Hsp90–GCH1
Interaction and BH4 Concentrations, and Restores
Endothelial Function in a Lamb Model of Pulmonary
Hypertension Secondary to Increased Pulmonary Blood Flow
Finally, we determined whether restoring the L-arginine/
ADMA ratio would restore BH4 concentrations and NO
signaling in our lamb model. Our data indicate that supplemen-
tation with L-arginine enhanced the interaction of GCH1 with
Hsp90 (Figure 7F), significantly increased GCH1 protein con-
centrations (Figure 7G), and restored concentrations of both
BH4 (Figure 1D) and NOx (Figure 1G).
DISCUSSION
This study produced several important findings: (1) ADMA
mediates the degradation of GCH1, secondary to the disruption
of the Hsp90–GCH1 complex; (2) the ubiquitin–proteasome
pathway is involved in the ADMA-mediated degradation of
GCH1; (3) the ADMA-mediated degradation of GCH1 is
facilitated by the E3 ligase CHIP; (4) decreases in the formation
of the Hsp90–GCH1 complex lead to ubiquitination and the
degradation of GCH1, causing BH4 concentrations to decrease;
and (5) supplementation with L-arginine restores endothelial
function in a lamb model of pulmonary hypertension secondary
to increased pulmonary blood flow. Further, we validated these
events both in vitro using cultured PAECs, and in vivo using
a lamb model of CHD with increased pulmonary blood flow,
and we showed that these alterations lead to a decrease in NO
signaling. Therefore, our study provides insights into a novel
mechanism by which ADMA can indirectly reduce NO signal-
ing, at least in part, by stimulating the CHIP-dependent degra-
Figure 4. ADMA induces GCH1 ubiquitination and pro-
teasomal degradation in PAECs. PAECs were exposed or
not to ADMA in the presence or absence of the protea-
somal inhibitor MG132 (10 mM) for 2 hours, and then
whole-cell lysates were subjected to ubiquitinated protein
enrichment (AP), followed by Western blotting with an
anti-GCH1 antibody (IB). A representative image is shown.
In addition, the effect of MG132 on the ADMA-mediated
decrease in GCH1 protein concentrations was determined
by Western blot analysis, using an antibody raised against
GCH1. Loading was normalized by reprobing the mem-
branes with an antibody specific to b-actin. A represen-
tative image is shown. Densitometric values represent
mean 6 SEM (n 5 6). *P , 0.05 versus untreated cells.
†P , 0.05 versus ADMA alone. Finally, PAECs were
exposed or not exposed to ADMA in the presence or
absence of MG132 for 4 hours, and the effect on cellular
BH4 concentrations was determined. The presence of
MG132 attenuated the ADMA-mediated decrease in BH4
concentrations. Values represent mean 6 SEM (n 5 6).
*P , 0.05 versus untreated cells. †P , 0.05 versus ADMA
alone. ‡P , 0.05 versus MG132 alone. The decreases in
concentrations of NO induced by ADMA in response to
shear stress (15 minutes, 20 dyn/cm2) were reversed by
MG132 (D). Values represent mean 6 SEM (n 5 6). *P ,
0.05 versus no shear. †P , 0.05 versus shear alone. ‡P ,
0.05 versus shear 1 ADMA.
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dation of GCH1 and reductions in BH4 concentrations. Recent
evidence suggests that pulmonary vascular tone is regulated by
a complex interaction of vasoactive substances that are locally
produced by vascular endothelium. Endothelial injury, second-
ary to increased pulmonary blood flow or pressure, may disrupt
these regulatory mechanisms, and is a potential factor in the
development of pulmonary hypertension. Our previous studies
showed that uncoupled eNOS occurs before overt endothelial
dysfunction (24). The data in this study shed light on the com-
plex signaling pathways that regulate the generation of NO
from eNOS, by demonstrating that ADMA-induced eNOS un-
coupling in shunt lambs is, at least in part, attributable to a BH4
deficiency secondary to the disruption of Hsp90–GCH1 intera-
ctions and the induction of a CHIP-dependent proteasomal deg-
radation of GCH1.
ADMA is a newly identified cardiovascular risk factor, and
increasing evidence suggests that impaired vasodilation in
a variety of cardiovascular diseases is linked to the inhibition
of NO generation by ADMA (3, 4). Our recent studies showed
that ADMA can exert a direct inhibitory effect on NO signaling
by competing with L-arginine for binding to the active site of
eNOS (1). However, we also found that ADMA can exert an
indirect effect on eNOS coupling through its ability to cause
mitochondrial dysfunction and a decrease in Hsp90 chaperone
activity (1). Interestingly, recent studies suggest that GCH1
may also be a client protein of Hsp90 (8). GCH1 is the first,
rate-limiting enzyme of BH4 biosynthesis (7), and accumulating
evidence indicates that optimal concentrations of BH4 are
fundamental for the normal function of eNOS in endothelial
cells. A number of previous studies demonstrated that the
regulation of GCH1 can occur at a variety of levels, including
transcriptional, posttranscriptional, and posttranslational (6).
The data we present here, both in vitro and in vivo, demon-
strate that GCH1 can be posttranslationally regulated through a
ubiquitin-dependent degradation of the GCH1 protein that is
independent of changes in GCH1 mRNA concentrations, and
that in vivo, restoring the ADMA/L-arginine ratio can prevent
these alterations in GCH1 and BH4 and preserve NO signaling.
Our findings are supported by previous studies where exposure
of human umbilical vascular endothelial cells to high amounts
of glucose was found to increase 26S proteasome activity,
resulting in ubiquitinated GCH1 degradation (25). Moreover,
4-hydroxy-2-nonenal increases superoxide anion radical con-
centrations in bovine aortic endothelial cells via GCH1 protea-
somal degradation (9). Our data add to this knowledge, both by
identifying CHIP as the key ubiquitin ligase regulating GCH1
degradation, and by demonstrating the key role of Hsp90 in
regulating normal GCH1 function. Interestingly, our data also
suggest that increasing BH4 concentrations through supplemen-
tation with sepiapterin overcomes the negative regulation of
ADMA on NO signaling, suggesting that therapies based on
stimulating BH4 biosynthesis or preventing its degradation
through oxidant stress mechanisms could have clinical utility.
However, further studies will be required to test this possibility.
Hsp90 was shown to interact with a number of proteins that
are required for the efficient biosynthesis of NO, including
Figure 5. The ADMA-induced degradation of
GCH1 is the dependent on the C-terminus of
Hsp70-interacting protein (CHIP) in PAECs. PAECs
were exposed or not to ADMA for 2 hours, and
then whole-cell lysates were subjected to immuno-
precipitation (IP), using an antibody specific to
CHIP, and then analyzed by Western blot analysis,
using the specific antiserum raised against GCH1
protein (A). A representative image is shown, in-
cluding the control with IgG alone. Blots were then
stripped and reprobed for CHIP, to normalize for
the efficiency of immunoprecipitation. Densitomet-
ric analysis indicates that ADMA enhances the
association of GCH1 with CHIP (A). PAECs were
also transiently transfected with increasing
amounts (0, 0.5, 1, and 2 mg) of pcDNA-Myc-
carboxy terminus of Hsc70 interacting protein
(pcDNA-Myc-CHIP). Forty hours after tranfection,
whole-cell lysates (20 mg) were prepared, and
protein concentrations of GCH1 and Myc-CHIP
were determined by immunoblotting with anti-
GCH1 and anti-Myc. A representative image is
shown, along with the densitometric analysis
indicating that the overexpression of CHIP dose-
dependently decreases GCH1 protein concentra-
tions (B). Loading was normalized by reprobing the
membranes with an antibody specific to b-actin. In
addition, whole-cell lysates prepared form PAECs
transfected with pcDNA-Myc-CHIP or the parental
vector (PCDNA3, 2 mg) were subjected to immu-
noprecipitation (IP), using an antibody specific to
Hsp90 (C ) or Hsp70 (D), and then analyzed by
Western blotting (IB), using a specific antiserum
raised against GCH1. A representative image is
shown for each Western blot. Blots were also stripped and reprobed for Hsp90 or Hsp70, to normalize for the efficiency of immunoprecipitation.
Densitometric values were then obtained for each band. The overexpression of CHIP significantly reduces the interaction of GCH1 with Hsp90, and
enhances its interaction with Hsp70. Values represent mean 6 SEM (n 5 4–6). *P , 0.05 versus empty vector transfection without ADMA treatment.
†P , 0.05 versus overexpression of CHIP or empty vector transfection with ADMA treatment.
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eNOS (26), soluble guanylate cyclase (27), and (as we showed
here) GCH1 (8). In cells, GCH1 is a pentamer that forms
a further complex structure with a pentamer of the GCH1
feedback regulatory protein (7). An examination of this multi-
meric structure implies regions that are similar in charge and
hydrophobicity to those found in eNOS, and that interact with
Hsp90 according to Fontana and colleagues (28). This suggests
that Hsp90 may be necessary to maintain this complex in
a conformation required for the biosynthesis of BH4. Consistent
with previous studies, our present data demonstrate that Hsp90
appears to be a newly described client protein for GCH1, and
that the levels of this interaction are reduced in ADMA-treated
PAECs and in a lamb model of CHD with increased pulmonary
blood flow and elevated concentrations of ADMA. This may be
the case because ADMA decreases the generation of ATP (1),
and the interaction of Hsp90 with its client proteins is ATP-
dependent (29). Many Hsp90 client proteins are brought into
complex with Hsp90 by a multiprotein Hsp90/Hsp70–based
chaperone machinery (21), and Hsp70 appears to be involved
in both the folding and degradation of Hsp90-client proteins
(22). Our data show that an increased interaction of Hsp70 with
GCH1 correlates with increases in GCH1 ubiquitination and
degradation, both in vitro and in vivo. Most proteins are
targeted for degradation by the 26S proteasome after ubiquitin
has been covalently attached in the form of a polyubiquitin
chain, with linkages involving lysine 48 functioning as a degra-
dation signal (30). Our data, along with previous studies,
indicate that the ubiquitin–proteasomal pathway is involved in
the degradation of GCH1 (9, 25). Ubiquitin-dependent protea-
somal degradation is a highly regulated process. The selectivity
of protein degradation is determined primarily at the stage of
ligation to ubiquitin (23). Ubiquitin–protein ligation requires
a cascade of three enzymes, E1 ubiquitin–activiting enzyme, E2
ubiquitin–conjugating enzyme, and E3 ubiquitin ligases (23).
CHIP is an E3 ubiquitin ligase, and was recently identified as an
Hsp90 cofactor (26). Although CHIP is a ubiquitous protein, its
high level of expression in heart and endothelial cells suggests
that CHIP may interact with proteins playing important roles
in cardiovascular function (26). Our results indicate that in
PAECs, CHIP is associated with GCH1 in a complex with
Hsp90 and Hsp70, and the association of GCH1 and CHIP is
increased when concentrations of ADMA are elevated. We also
found that the overexpression of CHIP decreased endogenous
GCH1 protein concentrations in PAECs. Furthermore, the
overexpression of CHIP acted synergistically with ADMA to
enhance the degradation of GCH1. A similar role for CHIP was
reported in the degradation of soluble guanylyl cyclase and
neuronal NO synthase (27, 31). CHIP has an important and
unique U-box domain in the C-terminal region that is re-
sponsible for ubiquitin ligase activity (17). To evaluate the
effects of the U-box domain of CHIP on the ADMA-mediated
degradation of GCH1, a U-box domain point mutant CHIP was
produced that lacks the ability to ubiquitinate ligase. Because
the U-box domain mutant CHIP is a dominant-negative protein
(17), the binding and sequestration of GCH1 from endogenous
CHIP by the overexpression of the U-box domain mutant CHIP
resulted in abolished CHIP-facilitated GCH1 degradation in
both the presence and absence of ADMA and the maintenance
of NO signaling. However, in contrast to the similar effects of
CHIP and ADMA on decreased GCH1 protein concentrations,
CHIP overexpression alone did not significantly decrease
concentrations of BH4, although the BH4/BH2 ratio was de-
creased. One possible explanation could be that, unlike
ADMA, CHIP over-expression does not change concentrations
of reactive oxygen species (ROS), and BH4 is a molecular target
of ROS (32). Furthermore, the regulation of net BH4 bio-
availability in endothelial cells is likely the result of a complex
equilibrium between the de novo synthesis pathway and the
salvage pathway. In the salvage pathway, sepiapterin can be
reduced by sepiapterin reductase to BH2, and further reduced
by dihydrofolate reductase (DHFR) to form BH4 (6). Recent
studies revealed that DHFR plays a critical role in maintaining
the BH4/BH2 ratio (33), which in turn plays an important role
in regulating eNOS coupling.
Figure 6. The U-box domain of CHIP is required for the ADMA-mediated degradation of GCH1 in PAECs. PAECs were transiently transfected with
pcDNA-Myc-CHIP, a U-box domain mutant CHIP (U-box-mCHIP), or the parental vector (pcDNA3). Forty hours after transfection, cells were
exposed or not exposed to ADMA for 2 hours, and then whole-cell lysates (20 mg) were prepared and protein concentrations of GCH1 and Myc-
CHIP were determined by immunoblotting with anti-GCH1 or anti-Myc, respectively. b-actin was used as an SDS-PAGE loading control. A
representative image is shown (A). The U-box mutant CHIP attenuates the ADMA-mediated degradation of GCH1 (A). In addition, concentrations of
BH4 and BH2 were determined by HPLC. Although no synergistic effect of CHIP and ADMA occurred in decreasing cellular BH4 concentrations,
a significant synergistic decrease in the BH4/BH2 ratio did occur. Values represent mean 6 SEM (n 5 6). *P , 0.05 versus pcDNA3. †P , 0.05 versus
overexpression of CHIP. The overexpression of CHIP alone decreased concentrations of NO in response to shear stress (15 minutes, 20 dyn/cm2),
and this was potentiated in the presence of ADMA (D). The overexpression of the U-box mutant CHIP attenuated the negative effects of ADMA on
the generation of NO in response to shear stress (D). Values represent mean 6 SEM (n 5 6). *P , 0.05 versus no shear. †P , 0.05 versus shear alone.
‡P , 0.05 versus wild-type (WT) CHIP 1 shear. $P , 0.05 versus wild-type CHIP 1 shear 1 ADMA.
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Figure 7. The decrease in Hsp90–GCH1 interactions, and the increase in CHIP–GCH1 interactions and protein ubiquitination, are recapitulated in
lambs with increased pulmonary blood flow. Protein extracts were prepared from peripheral lungs of Shunt and control lambs, and subjected to
immunoprecipitation (IP), using antibodies specific to Hsp90, Hsp70, or CHIP, and then analyzed by Western blotting (IB), using a specific antiserum
raised against GCH1. In addition, a reverse IP was performed using CGH1, and then analyzed by IB for Hsp90 (B). Tissue lysates were also subjected
to ubiquitinated protein enrichment (AP), followed by IB with an anti-GCH1 antibody. The concentrations of GCH1 associated with Hsp90 (A and B)
are significantly reduced in Shunt lambs, whereas the interactions of GCH1 with Hsp70 (C ) and CHIP (D) are significantly increased. A significant
increase in ubquitinated (Ub) GCH1 also occurred in Shunt lambs (E ). Supplementation with L-arginine significantly increased both GCH1–Hsp90
interactions (F ) and GCH1 protein concentrations (G) in Shunt lambs. Densitometric values represent mean 6 SEM (n 5 6). *P , 0.05 compared
with age-matched control lambs (A–E ) or vehicle-treated Shunt lambs (F and G).
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In conclusion, our data elucidate the effects of ADMA on BH4
deficiency both in vitro and in vivo, and suggest an important role
for the CHIP-mediated ubiquitin–proteasomal degradation of
GCH1 in the regulation of eNOS uncoupling. Our study suggests
that preventing or attenuating the ADMA-induced degradation
of GCH1 using L-arginine supplementation constitutes a potential
therapeutic approach for the treatment of endothelial dysfunction
associated with pulmonary hypertension.
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